Diabetic retinopathy remains the most frequent cause of newly diagnosed blindness in the working-age population. This is despite improvements in therapies for blood glucose and blood pressure control, and the many different treatment modalities that are currently available including laser, vitreous surgery, and intravitreal injections.
Corticosteroids

Intravitreal Triamcinolone Acetonide
Intravitreal triamcinolone acetonide (IVTA) has been used for treatment of DME. IVTA has also been used as an adjunct for patients undergoing panretinal photocoagulation (PRP) to reduce post-laser macular edema, prior to macular laser photocoagulation to reduce edema, and intraoperatively to better visualize the posterior cortical vitreous, and to decrease post-operative vascular permeability. Limited retrospective and prospective studies have shown improvements or stabilization of visual acuity in the short term, especially in patients with cystoid macular edema. [10] [11] [12] [13] [14] [15] In a prospective randomized trial the best corrected visual acuity (BCVA) improved by ≥5 letters after two years in 56 % of treated eyes, compared with 26 % of eyes in the placebo group. 15 An increase in intraocular pressure (IOP) of ≥5 mmHg was observed in 68 % of treated eyes. Glaucoma medication was required in 44 %, and surgery was required in 5 % of the treated eyes. Cataract surgery was performed in 54 % of treated eyes within the two-year follow-up period. There was one case of infectious endophthalmitis in the treatment group.
In another study, 88 eyes with DME were randomized to 4 mg IVTA or laser photocoagulation. 16 Patients were assessed and treated every four months. Optical coherence tomography (OCT) showed a reduction in central subfield thickness (CST) of 82.0 μm with IVTA and 62.3 μm with laser at 12 months. The ETDRS scores remained the same in both groups.
In the IVTA group, 22 of 43 eyes required ocular antihypertensives, and one eye developed sterile endophthalmitis. This study did not show a benefit from intravitreal triamcinolone over conventional laser therapy for patients with chronic DME.
Higher-dose IVTA may be associated with improved outcomes as well as increased side effects. In a study of 63 eyes of 63 patients with DME, the eyes were randomized to 4, 6, and 8 mg IVTA. Although all groups demonstrated improvement in BCVA and macular thickness, the mean BCVA improvement at six months was significantly higher in the 8 mg group. Elevated IOP occurred in 39 % of the 4 mg and 55 % of the 8 mg group. 17 The combination of IVTA and macular laser photocoagulation was studied in 86 eyes with diffuse DME who were randomized to IVTA alone or IVTA followed by macular laser photocoagulation three weeks later. The logarithm of the minimum angle of resolution (logMAR) visual acuity was significantly better in the combination group at three and six months. focal laser photocoagulation to 1 mg or 4 mg IVTA for treatment of DME.
Eight hundred forty eyes with DME were randomized to macular laser Experimental Treatments for Diabetic Macular Edema
The Fluocinolone aceinoide macular edema (FAME) study consists of two masked, randomized, multicenter trials that are fully enrolled, with 956 patients in the US, Canada, Europe, and India who will be followed up for 
Nova63035
Nova63035 (Novagali) is an injectable emulsion that contains a tissue-activated corticosteroid prodrug. The prodrug is converted into the drug by the enzymes that are present in the retina and choroid.
A Phase I non-randomized, open-label, dose-escalation clinical study to assess the safety and tolerability of Nova63035 in patients with DME is currently recruiting participants. The Safety and efficacy of ranibizumab in DME (RESOLVE) study is a randomized, double-masked, multicenter, Phase II study assessing the safety and efficacy of two concentrations of intravitreal ranibizumab
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injections compared with non-treatment control for the treatment of DME with center involvement. This study is ongoing, but is not recruiting participants.
The Combined approach to treatment using ranibizumab and efalizumab for DME (CAPTURE) study is a Phase I randomized, open-label, dose-comparison, safety/efficacy study evaluating combination treatment using ranibizumab and efalizumab (Raptiva ® , Genentech) for DME. 
Bevacizumab (Avastin)
Bevacizumab (Avastin ® , Genentech) is a full-length humanized antibody against all isoforms of VEGF. Small series have shown short-term improvement in DME, regression of proliferative retinopathy, clearing of vitreous hemorrhage and regression of rubeosis. [25] [26] [27] [28] [29] [30] The DRCRnet study group recently reported on a Phase II randomized clinical trial of intravitreal bevacizumab in DME. 31 The group provided data on the short-term effect of intravitreal bevacizumab in DME. One hundred and twenty-one eyes of 121 subjects with DME and BCVA ranging from 20/32 to 20/320 were randomized to one of five groups
• focal photocoagulation at baseline;
• intravitreal injection of 1.25 mg bevacizumab at baseline and six weeks;
• intravitreal injection of 2.5 mg bevacizumab at baseline and six weeks; intravitreal bevacizumab can reduce DME in some eyes, but the study was not designed to determine whether treatment is beneficial.
Pegaptanib
VEGF levels have been found to be elevated in the vitreous and the anterior chamber samples in patients with diabetic retinopathy. , was studied in Phase III trials and showed a significant reduction in vitreous hemorrhage which allowed laser treatment. 36, 37 No serious safety issues were reported and the incidence of retinal detachment was not statistically different between treated eyes and control groups. The study did not report on PVD induction. Animal studies of intravitreal hyaluronidase in rabbit eyes did not demonstrate an increase in induction of PVD. 38 Vitrase is currently not FDA approved for treatment of vitreous hemorrhage although it has been used off-label.
Plasmin is a non-specific protease mediating the fibrinolytic process.
It also acts on glycoproteins including laminin and fibronectin, present A Phase 2 trial is underway.
iCo-007
Multiple growth factors are implicated in the etiology of DME and diabetic 
Ruboxistaurin (Arxxant)
Hyperglycemia increases serum and cellular levels of diacylglycerol, which is a physiologic activator of protein kinase C (PKC). Activated PKC levels are associated with both increased levels of VEGF and increased vascular permeability. 45, 46 Ruboxistaurin (RBX) is a selective inhibitor of PKC. A Phase III study indicated that 32 mg/day RBX taken orally was effective in delaying the occurrence of moderate visual loss. Moderate visual loss occurred in 9.1 % of placebo-treated patients versus 5.5 % of RBX-treated patients.
Visual improvement of >15 letters was seen in 4.9 % treated versus 2.4 % placebo. Laser treatment for macular edema was reduced in the treated group, but a reduction in progression of diabetic retinopathy from moderately severe to very severe was not observed. 47 The PKC inhibitor DME study (PKC-DMES) group reported the 30-month results of a multicenter, double-masked, randomized clinical trial evaluating the safety and efficacy of orally administered RBX in patients with DME.
Six hundred eighty-six patients received placebo or RBX orally (4, 16, or 32 mg/day) for 30 months. The primary study outcome was progression to sight-threatening DME or application of macular photocoagulation for DME. The delay in progression to the primary outcome was not statistically significant. RBX was well-tolerated in this study. 48 The FDA has requested additional trials before approval of RBX. 
Octreotide
Topical Medications
Mecamylamine (CoMentis) inhibits endothelial nicotinic acetylcholine (nACh) receptors and decreases angiogenesis and vascular permeability. A Phase II study of the safety and bioactivity of topical ocular mecamylamine administered twice a day for 12 weeks for the treatment of DME has recently been completed. Bromfenac (Xibrom™, ISTA) is a non-steroidal anti-inflammatory drug (NSAID) that is currently undergoing a non-randomized, open-label, uncontrolled Phase I pilot study for treatment of DME.
Conclusions
Treatment of DME remains a major challenge despite improvements in in the treatment of patients with DME and peripheral capillary non-perfusion. It is important to realize that short-term visual improvements with the new experimental treatments are exciting, but one must use caution as DME may be a long-term chronic problem. n
